Siegfried Holding AG (SGFEF) Q2 2026 Earnings Report

The call balanced clear operational and strategic progress (top-line growth, margin expansion, strong commercial traction, successful technology and site milestones, acquisition integration on track) against near-term financial impacts from the acquisition (lower operating cash flow, higher inventory and leverage, and FX headwinds). Management reconfirmed guidance and emphasized focus on cash generation and deleveraging, with multiple execution milestones supporting the strategic outlook.

Management reconfirmed full‑year 2026 guidance of high single‑digit revenue growth in local currencies and a core EBITDA margin above 23%. In H1 they reported net sales of CHF 633m (+2.2% reported, +4.8% L.C.), with Drug Substances CHF 431.1m (68.1% of sales) and Drug Products CHF 201.9m; core EBITDA margin rose to 22.4% from 21.6% (an 80 bps improvement) and core gross profit was CHF 170.7m (+4.7% YoY). Cash and balance‑sheet metrics: operating cash flow CHF 93.7m (vs CHF 149.6m prior), free cash flow CHF 15.1m, acquisition cash outflows CHF 157.4m, financing inflows CHF 143.3m, and net debt to core EBITDA of 2.3x; the acquisition is expected to contribute roughly USD 100m on an annualized basis, USD exposure rose to 14% in H1 (forecast ~20% for FY) and management assumes an approximately 2% FX headwind for the year. Capital allocation and execution priorities were reiterated: CapEx targeted in the low‑teens of sales (moving closer to 10%), focus on cash generation and deleveraging, and operational milestones include freeing 80 m3 of U.S. capacity (available from 2028) with first transfers this year and first revenues from new U.S. business expected in 2027.